|Bid||53.51 x 1800|
|Ask||53.80 x 900|
|Day's Range||48.75 - 56.91|
|52 Week Range||41.33 - 277.80|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||183.40|
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) both delivered major returns for investors in the early days of the coronavirus vaccine race. Moderna's vaccine entered the market in December of 2020. Novavax's vaccine began winning authorizations a year later -- but isn't yet approved in the United States.
What happened Shares of Novavax (NASDAQ: NVAX) were tumbling 9.7% as of 11:28 a.m. ET on Tuesday. The company didn't make any announcements that would explain the decline. Instead, Novavax's fall appears to be primarily a result of the overall stock market turmoil with all of the major market indexes sinking today.
Since the curtains opened on 2022, the iconic Dow Jones Industrial Average, benchmark S&P 500, and growth-focused Nasdaq Composite, have respective fallen by 14%, 18%, and 27%. Losing more than a quarter of its value has pushed the Nasdaq firmly into a bear market. Although a tumbling stock market can be scary and tug on investors' emotions, big declines have always represented a buying opportunity.